• In January 2026, Illumina announced the launch of its Billion Cell Atlas alliance, naming Eli Lilly as a founding member in a program that uses CRISPR-based, large-scale genomic perturbation data and AI to map disease biology across more than 200 cell lines and hundreds of cell types.
• By mid-July 2026, the Atlas had already sequenced over 350 million cells and generated several petabytes of data, positioning Lilly closer to the core of AI-driven target discovery and mechanistic insights for future therapies.
• Now we’ll examine how Lilly’s deeper role in Illumina’s Billion Cell Atlas could reshape its investment narrative around R&D productivity and innovation.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Eli Lilly Investment Narrative Recap

To own Lilly, you have to believe its obesity, diabetes, and neuroscience franchises can justify a premium valuation while its R&D engine keeps delivering new products. The Billion Cell Atlas alliance reinforces the innovation story, but it does not materially change the near term focus on obesity drug execution as the key catalyst or on pricing, reimbursement, and competitive pressure as the biggest current risks.

In that context, Lilly’s recent decision to raise full year 2026 revenue guidance to US$82 billion to US$85 billion stands out. It underlines how management is leaning into demand for its incretin portfolio while continuing to spend aggressively on external platforms like Illumina’s Atlas and other AI or CRISPR collaborations, which could either support future growth or magnify the impact of any pipeline disappointments.

Yet beneath the optimism around AI driven discovery, investors should also be aware of...

Eli Lilly's narrative projects $113.8 billion revenue and $46.1 billion earnings by 2029.

Uncover how Eli Lilly's forecasts yield a $1243 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts took a much more cautious view, assuming revenue of about US$102.4 billion and earnings of roughly US$40.2 billion by 2029, reminding you that opinions on how alliances like the Billion Cell Atlas influence Lilly’s future can differ sharply and may shift as new data and partnerships emerge.

Explore 19 other fair value estimates on Eli Lilly - why the stock might be worth 22% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.